• In vitro study demonstrated CAR-NK-EVs killed 87.8% of TNBC cells and significantly reduced lung cancer cell viability
• CAR-NK-EVs showed superior anti-proliferative and pro-death effects compared to controls
• Potential advantages of CAR-exosomes over autologous CAR-T therapies in solid tumours

INOVIQ Limited has responded to ASX queries regarding its recent announcement about its new cancer treatment killing 88% of breast and lung cancer cells in lab tests. The company states that the header of the announcement conveyed a fair and balanced impression of the contents, as it clearly indicated the research was conducted in an in vitro laboratory environment. INOVIQ believes it had a reasonable basis to make the forward-looking statements about the potential advantages of its CAR-NK-EV therapy over autologous CAR-T therapies, as these are well-known in the scientific literature. The company justifies the use of the term 'treatment' as the in vitro study used a standard treatment-control design, which is required for regulatory acceptance and scientific rigour. The in vitro studies were conducted by INOVIQ, not the Peter MacCallum Cancer Institute as previously disclosed. The studies demonstrated that INOVIQ's CAR-NK-EV treatment exerted a significant cytotoxic effect, killing 87.8% of TNBC cells and significantly reducing the viability of lung cancer cells, with statistically significant results. INOVIQ confirms it has disclosed all relevant information and that the announcement is not misleading by omission.

The potential advantages of CAR-exosomes over autologous CAR-T therapies in solid tumours include that they could be faster to produce, safer to use, and more effective than traditional cell therapies.